Recent clinical trials have demonstrated that targeting LAG-3 with monoclonal antibodies, such as relatlimab, in combination with PD-1 inhibitors can enhance T-cell activation and promote a more robust anti-tumor immune response. Here, LAG3 is linked to neoplasm.